Good MorningEquity markets remained relatively steady on Wednesday, following the release of the CPI report and news of progress in trade negotiations. The CPI was cooler than expected, alleviating some but not all fears that tariffs would accelerate inflation. The risk is that the tariff impact isn't fully priced into the economy, and subsequent data will reflect it. The takeaway is that the FOMC is no closer to cutting rates than before the release, although the White House is sure to press for it.
Regarding the trade negotiations, the news is that a framework for a deal has been made and is to be approved by Trump and Xi. The caveat is that a framework isn't a deal, and there is still a long way to go before the endgame. Until then, Commerce Secretary Lutnick says there will be no further changes to tariffs on China, providing some stability to the outlook. Featured: Get Ahead with This Free Report! (Ad) 
|
Markets | | |
Parents beware. Christmas came early in 2025 as Nintendo Co., Ltd. (OTCMKTS: NTDOY) released its hotly anticipated Switch 2 handheld gaming console. It comes with a hefty price tag of $449.00.
However, investors who bought NTDOY stock earlier this year may easily have enough... Read the Full Story |
|
From Our Partners | | SpaceX value has surged to $350 billion...
Delivering windfall profits to early investors including Elon Musk and Peter Theil.
Right now, you can invest in "the next SpaceX" while its valuation is still below $100 million. | | Just click here for details inside my free report |
|
Stocks | | | Wall Street’s rally stalled on Wednesday after U.S. stocks climbed back within 2% of their all-time high. The S&P 500 fell 0.3% for its first loss in four days. The Dow Jones Industrial Average was virtually unchanged after edging down by 1 point, and the Nasdaq composite slipped 0.5%. Several B... Read the Full Story |
|
Stocks | | | U.S. stock indexes ticked higher on Thursday following another encouraging update on inflation across the country. The S&P 500 rose 0.4% to pull back with 1.6% of its record. The Dow Jones Industrial Average added 101 points, or 0.2%, and the Nasdaq composite gained 0.2%.Oracle pushed upward on ... Read the Full Story |
|
From Our Partners | | Those who recognized the opportunity early didn’t hesitate—they took action.
Now it’s your turn.
We are about to release a brand-new report featuring a company with massive breakout potential.
Here’s the best part: This report is 100% free. No hidden fees, no catch—just expert research designed to keep you ahead of the market. | | ➡️ Click here now to claim your free report! |
|
Markets | | | Conventional investor wisdom holds that the consumer discretionary sector performs best when the economy is thriving and customers have money to spend. Low interest rates and strong job growth may be other important indicators of a potential boom in consumer discretionary companies.
With those thin... Read the Full Story |
|
Markets | | |
Dave & Buster's (NASDAQ: PLAY) FQ1 results and outlook for the year affirm that its CEO change and Back-to-Basics strategy were the right move. The critical detail is that this heavily shorted market is amid a short-covering rally and rebound that will result in a complete price reversal and... Read the Full Story |
|
From Our Partners | | AI breakthroughs. Inflation shocks. Energy rotations.
The market is moving fast — and the biggest winners often start small.
At Street Ideas, we focus on small-cap companies showing early momentum — before the crowd piles in. | | “3 Under-the-Radar Stocks Triggering Early Signals” |
|
Markets | | | Spain's economy minister says the millions of tourists who visit the country every year present a challenge for Spain's residents that the government can no longer afford to ignore. Last year, Spain received a record 94 million international visitors, making it one of the most visited countries in t... Read the Full Story |
|
Markets | | | The world’s most powerful politician and its richest businessman stepped back from their war of words that stunned Washington and Wall Street alike last week, but it's unclear if the peace will hold. Early Wednesday, Musk wrote on X, “I regret some of my posts about President @realDonaldTrump last w... Read the Full Story |
|
Markets | | |
There was absolutely nothing wrong with GitLab’s (NASDAQ: GTLB) Q1 earnings report and guidance. Nothing that is, except a wee bit of tepidness relative to analysts' relatively high bar. The sticking point, the cause for the 12% post-release price plunge, is that the guidance for Q2 r... Read the Full Story |
|
Markets | | | The Environmental Protection Agency on Wednesday proposed repealing rules that limit planet-warming greenhouse gas emissions from power plants fueled by coal and natural gas, an action that Administrator Lee Zeldin said would remove billions of dollars in costs for industry and help “unleash” Americ... Read the Full Story |
|
Markets | | |
In mid-June 2025, space-based cellular broadband provider AST SpaceMobile Inc. (NASDAQ: ASTS) reached its highest share price in nearly 10 months, with analysts viewing the stock optimistically and calling for nearly 19% further upside potential.
But a five-day return of more than 38% could sca... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. | | View Today's Stock Pick |
|
